KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accumulated Expenses (2018 - 2019)

Historic Accumulated Expenses for Arbutus Biopharma (ABUS) over the last 7 years, with Q4 2019 value amounting to $137000.0.

  • Arbutus Biopharma's Accumulated Expenses fell 8970.7% to $137000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $137000.0, marking a year-over-year decrease of 8970.7%. This contributed to the annual value of $137000.0 for FY2019, which is 8970.7% down from last year.
  • Per Arbutus Biopharma's latest filing, its Accumulated Expenses stood at $137000.0 for Q4 2019, which was down 8970.7% from $203000.0 recorded in Q3 2019.
  • Arbutus Biopharma's 5-year Accumulated Expenses high stood at $1.9 million for Q2 2015, and its period low was $28000.0 during Q1 2015.
  • Moreover, its 3-year median value for Accumulated Expenses was $647000.0 (2015), whereas its average is $736125.0.
  • The largest annual percentage gain for Arbutus Biopharma's Accumulated Expenses in the last 5 years was 2160.1% (2015), contrasted with its biggest fall of 9797.25% (2015).
  • Over the past 3 years, Arbutus Biopharma's Accumulated Expenses (Quarter) stood at $952000.0 in 2015, then skyrocketed by 39.81% to $1.3 million in 2018, then plummeted by 89.71% to $137000.0 in 2019.
  • Its Accumulated Expenses was $137000.0 in Q4 2019, compared to $203000.0 in Q3 2019 and $342000.0 in Q2 2019.